Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;23(2):195-202.
doi: 10.1007/s40272-021-00438-2. Epub 2021 Mar 13.

Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart

Tino Mienert  1 , Anoosh Esmaeili  2 , Blanka Steinbrenner  1 , Markus Khalil  1 , Matthias Müller  1 , Hakan Akintuerk  1 , Gunter Kerst  3 , Dietmar Schranz  4   5
Affiliations
Observational Study

Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart

Tino Mienert et al. Paediatr Drugs. 2021 Mar.

Abstract

Background: Newborns with hypoplastic left heart (HLH) are usually palliated with the Norwood procedure or a hybrid stage I procedure. Hybrid is our preferred approach. Given the critical relationship between stage I, interstage, and comprehensive stage II or advanced biventricular repair, we hypothesized that appropriate drug treatment is a significant therapeutic cornerstone, especially for the management of the high-risk interstage.

Methods: We report a single-center observational study addressing the cardiovascular effects of, in particular, oral β-blockers and the additional use of angiotensin-converting enzyme (ACE) and mineralocorticoid inhibitors.

Results: In total, 51 newborns-30 with HLH syndrome (HLHS) and 21 with HLH complex (HLHC)-with a median bodyweight of 3.0 kg (range 1.9-4.4; nine with bodyweight ≤ 2500 g) underwent an uneventful "Giessen hybrid approach" using a newly approved duct stent. All patients were discharged home with a single, double or triple therapy consisting of ß-blockers, ACE and mineralocorticoid inhibitors; 90% of the patients received bisoprolol, 10% received propranolol, 72% received lisinopril, and 78% received spironolactone. Resting heart rate decreased from 138 bpm (range 112-172; n = 51) at admission to 123 bpm (range 99-139; n = 51) at discharge and 110 bpm before stage II/biventricular repair/heart transplantation (range 90-140; n = 37) accompanied by favorable bodyweight gain. No side effects were evident.

Conclusion: In view of drug risk/benefit profiles, as well as the variable morphology and hemodynamics, the highly selective β1-adrenoceptor blocker bisoprolol is our preferred drug for treatment of HLHS/HLHC in the interstage. We avoid using ACE inhibitor monotherapy and exclude potential risks for coronary and cerebral perfusion pressure beforehand.

PubMed Disclaimer

Conflict of interest statement

Tino Mienert, Anoosh Esmaeili, Blanka Steinbrenner, Markus Khalil, Matthias Müller, Hakan Akintuerk, Gunter Kerst, and Dietmar Schranz have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Summary of the follow-up surgeries after hybrid stage I. BVR biventricular repair, ccTGA congenital corrected transposition of the great arteries, HLHC hypoplastic left heart complex, HLHS hypoplastic left heart syndrome, HTX heart transplantation, LV left ventricle, TCPC total cavo-pulmonary connection
Fig. 2
Fig. 2
Body weight data from patients with hypoplastic left heart syndrome at admission and discharge, and weight gain before comprehensive stage II
Fig. 3
Fig. 3
Echocardiographic four-chamber view showing the volume-loaded RV in hypoplastic left heart syndrome before (a) and unloaded and hypertrophied after comprehensive stage II (b). Based on this well-known phenomenon following comprehensive stage II, we hypothesized that a bisoprolol–lisinopril–spironolactone treatment strategy might be beneficial to reduce the severity of a diastolic dysfunctional RV. hLV hypoplastic left ventricle, LA left artery, LV left ventricle, RA right artery, RV right ventricle
See this image and copyright information in PMC

References

    1. Michel-Behnke I, Akintuerk H, Marquardt I, Mueller M, Thul J, Bauer J, Hagel KJ, Kreuder J, Vogt P, Schranz D. Stenting of the ductus arteriosus and banding of the pulmonary arteries: basis for various surgical strategies in newborns with multiple left heart obstructive lesions. Heart. 2003;89(6):645–650. doi: 10.1136/heart.89.6.645. - DOI - PMC - PubMed
    1. Zajonz T, Cupka P, Koerner C, Mann V, Menges T, Akintuerk H, Valeske K, Thul J, Schranz D, Mueller M. Anaesthesia for bilateral pulmonary banding a spart of hybrid stage I palliating neonates with hypoplastic left heart syndrome. Paediatr Anaesth. 2020 doi: 10.1111/pan.13876. - DOI - PubMed
    1. Schranz D, Bauer A, Reich B, Steinbrenner B, Recla S, Schmidt D, Apitz C, Thul J, Valeske K, Bauer J, Müller M, Jux C, Michel-Behnke I, Akintürk H. Fifteen-year single center experience with the “Giessen Hybrid” approach for hypoplastic left heart and variants: current strategies and outcomes. Pediatr Cardiol. 2015;36(2):365–373. doi: 10.1007/s00246-014-1015-2. - DOI - PMC - PubMed
    1. Yerebakan C, Murray J, Valeske K, Thul J, Elmontaser H, Mueller M, Mann V, Ostermayer S, Latus H, Apitz C, Schranz D. Akintuerk H (2014) Long-term results of biventricular repair after initial Giessen hybrid approach for hypoplastic left heart variants. J Thorac Cardiovasc Surg. 2015;149:1112–1120. doi: 10.1016/j.jtcvs.2014.09.028. - DOI - PubMed
    1. Yerebakan C, Valeske K, Elmontaser H, Yörüker U, Mueller M, Thul J, Mann V, Latus H, Villanueva A, Hofmann K, Schranz D. Akintuerk H (2015) Hybrid therapy for hypoplastic left heart syndrome: myth, alternative, or standard? J Thorac Cardiovasc Surg. 2016;151:1112–1121. doi: 10.1016/j.jtcvs.2015.10.066. - DOI - PubMed

Publication types

Substances

LinkOut - more resources